Beyond the Lab: How AI is Reshaping Portfolio Strategy, Capital Allocation, and R&D Investment in Biopharma

Session details:

AI’s influence on biopharma extends well beyond molecule design. Increasingly, it is informing how companies prioritize pipelines, allocate capital, and structure partnerships. By combining predictive models of trial success, payer uptake, and competitive dynamics with discovery insights, AI is giving leadership teams sharper tools to decide where to invest and when to pivot. This panel will explore how AI is being applied to portfolio strategy and business development, the impact on R&D investment decisions, and how boards and investors are weighing AI-driven analysis in today’s capital-constrained market.

Moderator: Stephanie Butler, Senior Conference Production Director, Fierce Life Sciences